1. Home
  2. MCY vs BLTE Comparison

MCY vs BLTE Comparison

Compare MCY & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury General Corporation

MCY

Mercury General Corporation

HOLD

Current Price

$103.62

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$147.72

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCY
BLTE
Founded
1961
2018
Country
United States
United States
Employees
4300
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.0B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
MCY
BLTE
Price
$103.62
$147.72
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $228.89
AVG Volume (30 Days)
★ 222.9K
133.0K
Earning Date
11-03-2026
11-09-2026
Dividend Yield
★ 1.19%
N/A
EPS Growth
★ 15.62
N/A
EPS
★ 8.20
N/A
Revenue
★ $5,992,468,000.00
N/A
Revenue This Year
$4.51
N/A
Revenue Next Year
$6.66
N/A
P/E Ratio
$13.02
★ N/A
Revenue Growth
★ 9.44
N/A
52 Week Low
$74.29
$90.84
52 Week High
$113.06
$200.00

Technical Indicators

Market Signals
Indicator
MCY
BLTE
Relative Strength Index (RSI) 52.10 39.67
Support Level $100.24 $145.21
Resistance Level $103.94 $161.08
Average True Range (ATR) 1.96 5.89
MACD 0.40 -0.37
Stochastic Oscillator 44.19 30.70

Price Performance

Historical Comparison
MCY
BLTE

About MCY Mercury General Corporation

Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: